文献速递帕金森病与运动障碍

帕金森病及LRRK2 G2019S变异携带者的嗅觉表现与运动衰退及发病年龄的关联

Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant.
PubMed 文献 · Neurology · 2022-06-03

研究纳入162例LRRK2帕金森病和198例特发性帕金森病患者,随访92例和74例,用高斯混合模型按嗅觉百分位分亚组,线性混合效应模型分析嗅觉亚组与运动/认知变化的关系。结果显示LRRK2帕金森病基线嗅觉优于特发性帕金森病,嗅觉最差组发病年龄更早且运动衰退更快,但嗅觉亚组与认知下降无显著关联。

要点

  • LRRK2帕金森病基线嗅觉优于特发性帕金森病,嗅觉减退比例更低。
  • LRRK2帕金森病中嗅觉最差组发病年龄早于其他组,运动衰退更快。
  • 嗅觉亚组与认知下降无显著关联。

核心结论

  • 在LRRK2 G2019S帕金森病中,嗅觉最差组发病年龄更早且运动衰退更快,嗅觉亚组与认知下降无显著关联。
  • 作者认为这支持LRRK2帕金森病存在一个可能在LRRK2相关药物临床试验中显示更快变化的亚组,并强调需将仔细的表型分型纳入LRRK2相关药物临床试验的分配方案。

研究设计与样本

  • 研究纳入来自LRRK2阿什肯纳兹犹太人联盟的162例LRRK2帕金森病患者和198例特发性帕金森病患者,随访数据分别有92例和74例。
  • 评估嗅觉(宾夕法尼亚大学嗅觉识别测试[UPSIT])、运动功能(统一帕金森病评定量表)、认知(蒙特利尔认知评估)以及睡眠、非运动和情绪。
  • 对UPSIT百分位评分应用高斯混合模型确定基于嗅觉表现的亚组,使用以帕金森病病程为时间尺度的线性混合效应模型评估UPSIT亚组归属与运动/认知变化的关系。

主要发现

  • LRRK2帕金森病基线嗅觉优于特发性帕金森病(平均UPSIT±标准差:24.2±8.8 vs 18.9±7.6),平均百分位评分更高(差异:15.3±11.6)(p < 0.001),嗅觉减退比例更低(55.6% vs 85.4%;p < 0.001)。
  • 分析提示LRRK2帕金森病存在3个亚组,嗅觉最差组(第1组)发病年龄早于第2组和第3组(54.5±11.1 vs 61.7±9.3)(p = 0.012),嗅觉减退组整体发病年龄也早于非嗅觉减退组(55.0±11.3 vs 61.7±9.1)(p < 0.001)。
  • LRRK2帕金森病中,UPSIT最差组的纵向运动恶化显著快于UPSIT最佳组(第3组 vs 第1组:B = 0.31,SE = 0.35 vs B = 0.96,SE = 0.28)(率差 = -0.65,SE = 0.29)(p = 0.03)。
  • 嗅觉亚组归属与认知下降无显著关联。

关键数值与推荐

  • 本研究提供II级证据:在LRRK2帕金森病患者中,更差的嗅觉评分与更早的症状性发病年龄和更快的运动衰退速率相关。

临床怎么用

  • 作者认为LRRK2帕金森病中嗅觉最差组可能代表一个在LRRK2相关药物临床试验中显示更快变化的亚组。
  • 作者强调需将仔细的表型分型纳入LRRK2相关药物临床试验的分配方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: There is clinical and phenotypic heterogeneity in LRRK2 G2019S Parkinson disease (PD), including loss of smell. Olfactory scores have defined subgroups of LRRK2 PD at baseline. We now extend this work longitudinally to better determine features associated with olfactory classes and to gain further insight into this heterogeneity. METHODS: Evaluation of 162 patients with LRRK2 PD and 198 patients with idiopathic PD (IPD) from the LRRK2 Ashkenazi Jewish Consortium was performed, with follow-up available for 92 patients with LRRK2 PD and 74 patients with IPD. Olfaction (University of Pennsylvania Smell Identification Test [UPSIT]), motor function (Unified Parkinson Disease Rating Scale), and cognition (Montreal Cognitive Assessment), as well as sleep, nonmotor, and mood, were measured. Gaussian mixture models were applied on the UPSIT percentile score to determine subgroups based on olfactory performance. Linear mixed effects models, using PD duration as the time scale, assessed the relationship between UPSIT subgroup membership and motor/cognitive change. RESULTS: Baseline olfaction was better in LRRK2 PD compared with IPD (mean UPSIT ± SD: 24.2 ± 8.8 vs 18.9 ± 7.6), with higher mean percentile scores (difference: 15.3 ± 11.6) (p < 0.001) and less frequent hyposmia (55.6% vs 85.4%; p < 0.001). Analysis suggested 3 classes among LRRK2 PD. Age at onset in LRRK2 PD was earlier in the worst olfaction group (group 1), compared with groups 2 and 3 (54.5 ± 11.1 vs 61.7 ± 9.3) (p = 0.012), and separately in the hyposmic group overall (55.0 ± 11.3 vs 61.7 ± 9.1) (p < 0.001). Longitudinal motor deterioration in LRRK2 PD was also significantly faster in the worst UPSIT group than the best UPSIT group (group 3 vs group 1: B = 0.31, SE = 0.35 vs B = 0.96, SE = 0.28) (rate difference = -0.65, SE = 0.29) (p = 0.03). However, olfactory group membership was not significantly associated with cognitive decline. DISCUSSION: In this large LRRK2 cohort with longitudinal analysis, we extend prior work demonstrating subgroups defined by olfaction in LRRK2 G2019S PD and show that the worst olfaction group has earlier age at PD onset and more rapid motor decline. This supports a subgroup of LRRK2 PD that might show more rapid change in a clinical trial of LRRK2-related agents and highlights the need to integrate careful phenotyping into allocation schema in clinical trials of LRRK2-related agents. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that worse olfactory scores were associated with an earlier age at symptomatic onset and a faster rate of motor deterioration in patients with LRRK2 PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Saunders-Pullman R, Ortega RA, Wang C, et al. Association of Olfactory Performance With Motor Decline and Age at Onset in People With Parkinson Disease and the LRRK2 G2019S Variant. Neurology. 2022. PMID: 35995594. doi:10.1212/WNL.0000000000200737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。